ACG Wealth purchased a new stake in shares of Sanofi (NASDAQ:SNY – Get Rating) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,531 shares of the company's stock, valued at approximately $127,000.
Several other large investors have also recently bought and sold shares of the stock. Archford Capital Strategies LLC acquired a new position in Sanofi during the second quarter valued at approximately $693,000. Transcend Capital Advisors LLC boosted its position in Sanofi by 10.0% during the second quarter. Transcend Capital Advisors LLC now owns 7,885 shares of the company's stock valued at $394,000 after purchasing an additional 720 shares during the last quarter. 180 Wealth Advisors LLC raised its stake in Sanofi by 6.3% in the second quarter. 180 Wealth Advisors LLC now owns 6,894 shares of the company's stock valued at $352,000 after buying an additional 410 shares during the period. Nkcfo LLC raised its stake in Sanofi by 289.9% in the second quarter. Nkcfo LLC now owns 210,750 shares of the company's stock valued at $10,544,000 after buying an additional 156,700 shares during the period. Finally, Old Port Advisors raised its stake in Sanofi by 7.4% in the second quarter. Old Port Advisors now owns 26,090 shares of the company's stock valued at $1,309,000 after buying an additional 1,787 shares during the period. 10.33% of the stock is owned by institutional investors and hedge funds.
Get Sanofi alerts:Wall Street Analysts Forecast Growth
Several analysts have issued reports on SNY shares. Morgan Stanley dropped their price objective on Sanofi from €112.00 ($114.29) to €93.00 ($94.90) in a research note on Thursday, September 8th. Kepler Capital Markets lowered Sanofi from a "buy" rating to a "hold" rating and dropped their price objective for the company from €120.00 ($122.45) to €89.00 ($90.82) in a research note on Wednesday, August 24th. StockNews.com upgraded Sanofi from a "buy" rating to a "strong-buy" rating in a research note on Sunday, August 14th. Cheuvreux lowered Sanofi from a "buy" rating to a "hold" rating in a research note on Wednesday, August 24th. Finally, Credit Suisse Group increased their target price on Sanofi from €105.00 ($107.14) to €110.00 ($112.24) and gave the stock an "outperform" rating in a research note on Friday, July 22nd. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $105.38.
Sanofi Price Performance
Sanofi stock opened at $39.13 on Friday. The stock's fifty day moving average price is $43.81 and its two-hundred day moving average price is $48.70. Sanofi has a one year low of $38.66 and a one year high of $58.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. The firm has a market cap of $99.19 billion, a PE ratio of 13.00, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53.Sanofi (NASDAQ:SNY – Get Rating) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.07. Sanofi had a return on equity of 25.99% and a net margin of 16.60%. The firm had revenue of $10.78 billion for the quarter, compared to analyst estimates of $10.32 billion. As a group, research analysts expect that Sanofi will post 4.14 EPS for the current fiscal year.
Sanofi Company Profile
(Get Rating)
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
See Also
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Get Rating).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.